DNA surely has a strong case for compensation. The finer details on likelyhood of success, and the likely amount is another thing. However, you are right, hard to buy it with legal woes hanging over it. I think it will re rate on operating performance, just not to comparative valutions of Asian casino stocks because of legal risk of lease termination. Which already seems highly unlikely given a Cambodian court effectively ruled against it by pre-emptively applying an injunction against it. What are the odds arbitration lauched by the Vendors comes to a different conclusiin?
Someone is accumulating, page-18
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
